A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
- 02 Dec 2016 Status changed from active, no longer recruiting to completed.
- 06 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2016 Status changed from not yet recruiting to recruiting.